Whether or not the use of metformin decreases the risk of gastric adenocarcinoma is unclear.
This was a population-based cohort study in 2005–2015. Associations between metformin use and gastric non-cardia and cardia adenocarcinomas were examined within two cohorts; a diabetes cohort of participants using anti-diabetes medications, and a matched cohort of common-medication users, where metformin non-users were frequency matched (10:1) with metformin users for sex and age. Multivariable Cox proportional hazard regression analyses provided hazard ratios (HR) and 95% confidence intervals (CI), adjusting for sex, age, calendar year, comorbidity, Helicobacter pylori eradication treatment, use of non-steroidal anti-inflammatory drugs or aspirin and use of statins.
During the follow-up for a median of 5.8 years, 892 (0.1%) participants in the diabetes cohort and 6395 (0.1%) participants in the matched cohort of common-medication users developed gastric adenocarcinoma. Metformin users had no significantly decreased risk of gastric non-cardia adenocarcinoma (diabetes cohort: HR 0.93, 95% CI 0.78–1.12; matched cohort: HR 1.30, 95% CI 1.18–1.42) or cardia adenocarcinoma (diabetes cohort: HR 1.49, 95% CI 1.09–2.02; matched cohort: HR 1.58, 95% CI 1.38–1.81) compared with non-users in both cohorts.
This cohort study with <10 years of follow-up suggests metformin use may not prevent gastric adenocarcinoma.
Subscribe to Journal
Get full journal access for 1 year
only $32.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C. et al. Global, Regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 4, 1553–1568 (2018).
Balakrishnan, M., George, R., Sharma, A. & Graham, D. Y. Changing trends in stomach cancer throughout the world. Curr. Gastroenterol. Rep. 19, 36 (2017).
Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K. & Prenen, H. Gastric cancer. Lancet 388, 2654–2664 (2016).
Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S. et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385, 977–1010 (2015).
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B. et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. 3, 1451–1461 (2010).
Singh, S., Singh, H., Singh, P. P., Murad, M. H. & Limburg, P. J. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidem. Biomark. 22, 2258–2268 (2013).
Zhang, Z. J., Zheng, Z. J., Shi, R., Su, Q., Jiang, Q. & Kip, K. E. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 97, 2347–2353 (2012).
Col, N. F., Ochs, L., Springmann, V., Aragaki, A. K. & Chlebowski, R. T. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res. Treat. 135, 639–646 (2012).
Daugan, M., Dufay Wojcicki, A., d’Hayer, B. & Boudy, V. Metformin: an anti-diabetic drug to fight cancer. Pharmacol. Res. 113(Pt A), 675–685 (2016).
Yu, G., Fang, W., Xia, T., Chen, Y., Gao, Y., Jiao, X. et al. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget 6, 12748–12762 (2015).
Chen, G., Feng, W., Zhang, S., Bian, K., Yang, Y., Fang, C. et al. Metformin inhibits gastric cancer via the inhibition of HIF1alpha/PKM2 signaling. Am. J. Cancer Res. 5, 1423–1434 (2015).
Courtois, S., Duran, R. V., Giraud, J., Sifre, E., Izotte, J., Megraud, F. et al. Metformin targets gastric cancer stem cells. Eur. J. Cancer 84, 193–201 (2017).
Zhou, X. L., Xue, W. H., Ding, X. F., Li, L. F., Dou, M. M., Zhang, W. J. et al. Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies. Oncotarget 8, 55622–55631 (2017).
Xie, S.-H., Santoni, G., Mattsson, F., Ness-Jensen, E. & Lagergren, J. Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH). BMJ Open 9, e023155 (2019).
Wettermark, B., Hammar, N., Fored, C. M., Leimanis, A., Otterblad Olausson, P., Bergman, U. et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol. Drug Saf. 16, 726–735 (2007).
Wallerstedt, S. M., Wettermark, B. & Hoffmann, M. The first decade with the swedish prescribed drug register—a systematic review of the output in the scientific literature. Basic Clin. Pharmacol. Toxicol. 119, 464–469 (2016).
Ekstrom, A. M., Signorello, L. B., Hansson, L. E., Bergstrom, R., Lindgren, A. & Nyren, O. Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J. Natl Cancer Inst. 91, 786–790 (1999).
Jakobsson, G. L., Sternegard, E., Olen, O., Myrelid, P., Ljung, R., Strid, H. et al. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scand. J. Gastroenterol. 52, 216–221 (2017).
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J. L., Reuterwall, C. et al. External review and validation of the Swedish national inpatient register. BMC Public Health 11, 450 (2011).
Brooke, H. L., Talback, M., Hornblad, J., Johansson, L. A., Ludvigsson, J. F., Druid, H. et al. The Swedish cause of death register. Eur. J. Epidemiol. 32, 765–773 (2017).
Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373–383 (1987).
Doorakkers, E., Lagergren, J., Gajulapuri, V. K., Callens, S., Engstrand, L. & Brusselaers, N. Helicobacter pylori eradication in the Swedish population. Scand. J. Gastroenterol. 52, 678–685 (2017).
Abnet, C. C., Freedman, N. D., Kamangar, F., Leitzmann, M. F., Hollenbeck, A. R. & Schatzkin, A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br. J. Cancer 100, 551–557 (2009).
Joo, M. K., Park, J. J. & Chun, H. J. Additional benefits of routine drugs on gastrointestinal cancer: statins, metformin, and proton pump inhibitors. Dig. Dis. 36, 1–14 (2018).
Olefson, S. & Moss, S. F. Obesity and related risk factors in gastric cardia adenocarcinoma. Gastric Cancer 18, 23–32 (2015).
Ekstrom, N., Schioler, L., Svensson, A. M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B. et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2, pii: e001076 (2012).
Steffen, A., Huerta, J. M., Weiderpass, E., Bueno-de-Mesquita, H. B., May, A. M., Siersema, P. D. et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer. 137, 646–657 (2015).
MacInnis, R. J., English, D. R., Hopper, J. L. & Giles, G. G. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int. J. Cancer. 118, 2628–2631 (2006).
Ruiter, R., Visser, L. E., van Herk-Sukel, M. P., Coebergh, J. W., Haak, H. R., Geelhoed-Duijvestijn, P. H. et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 35, 119–124 (2012).
Hsieh, M. C., Lee, T. C., Cheng, S. M., Tu, S. T., Yen, M. H. & Tseng, C. H. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp. Diabetes Res. 2012, 413782 (2012).
Valent, F. Diabetes mellitus and cancer of the digestive organs: an Italian population-based cohort study. J. Diabetes Complicat. 29, 1056–1061 (2015).
Kim, Y. I., Kim, S. Y., Cho, S. J., Park, J. H., Choi, I. J., Lee, Y. J. et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment. Pharmacol. Ther. 39, 854–863 (2014).
Cheung, K. S., Chan, E. W., Wong, A. Y. S., Chen, L., Seto, W. K., Wong, I. C. K. et al. Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication. J. Natl Cancer Inst. 111, 484–489 (2018).
Lee, M. S., Hsu, C. C., Wahlqvist, M. L., Tsai, H. N., Chang, Y. H. & Huang, Y. C. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11, 20 (2011).
Murff, H. J., Roumie, C. L., Greevy, R. A., Hackstadt, A. J., McGowan, L. E. D., Hung, A. M. et al. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Cancer Causes Control 29, 823–832 (2018).
Tseng, C. H. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging (Albany N Y). 8, 1636–1649 (2016).
Jee, S. H., Ohrr, H., Sull, J. W., Yun, J. E., Ji, M. & Samet, J. M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293, 194–202 (2005).
Xu, H. L., Tan, Y. T., Epplein, M., Li, H. L., Gao, J., Gao, Y. T. et al. Population-based cohort studies of type 2 diabetes and stomach cancer risk in Chinese men and women. Cancer Sci. 106, 294–298 (2015).
Zheng, J., Rutegard, M., Santoni, G., Wallner, B., Johansson, I., Sund, M. et al. Prediabetes and diabetes in relation to risk of gastric adenocarcinoma. Br. J. Cancer 120, 1147–1152 (2019).
Yamagata, H., Kiyohara, Y., Nakamura, S., Kubo, M., Tanizaki, Y., Matsumoto, T. et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care 28, 789–794 (2005).
Lin, S. W., Freedman, N. D., Hollenbeck, A. R., Schatzkin, A. & Abnet, C. C. Prospective study of self-reported diabetes and risk of upper gastrointestinal cancers. Cancer Epidemiol. Biomarkers Prev. 20, 954–961 (2011).
Kim, T. J., Lee, H., Min, Y. W., Min, B. H., Lee, J. H., Son, H. J. et al. Diabetic biomarkers and the risk of proximal or distal gastric cancer. J. Gastroenterol. Hepatol. 31, 1705–1710 (2016).
Ludvigsson, J. F., Haberg, S. E., Knudsen, G. P., Lafolie, P., Zoega, H., Sarkkola, C. et al. Ethical aspects of registry-based research in the Nordic countries. Clin. Epidemiol. 7, 491–508 (2015).
The authors declare no competing interests.
Ethics approval and consent to participate
The study was conducted conforming to the Declaration of Helsinki. According to the Swedish legislation (1998:543) on health data registries, informed consents were generally not needed for registry-based studies in Sweden if the studies had been approved by the local ethical board.43 This study was approved by Regional Ethical Review Board in Stockholm, Sweden (reference number 2016/982-3/4).
Consent for publication
This work was supported by Swedish Cancer Society (CAN 2015/460) and Swedish Research Council (SIMSAM D0547801). Both the founding resources were neither involved in the study design, data collection, data analysis and interpretation of the results nor in the writing of the report and in the decision to submit the article for publication.
All the data in this study were retrieved from the Swedish Prescribed Drugs and Health Cohort. The original data are available from the related registries listed above but restrictions apply to the availability of these data, which were used under license for this study and therefore are not publicly available. The data are, however, available through applications to these registries or reasonable request to the corresponding author (S.X.). The codes for the data analysis are archived by the biostatistician (G.S.).
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zheng, J., Xie, S., Santoni, G. et al. Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. Br J Cancer 121, 877–882 (2019). https://doi.org/10.1038/s41416-019-0598-z